Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch of its patent-pending ...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a ...
Cardio Diagnostics CDIO, a leader in artificial intelligence-driven precision cardiovascular medicine, has published a potentially revolutionary study in the Journal of the American Heart Association ...
Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (CDIO) (Nasdaq: CDIO), an AI-powered ...
Deepak L. Bhatt, MD, MPH: Let me turn now to Dr Navar to discuss what I think is an important part of the discussion. She’s done a lot of work on this. How do we actually estimate patients’ risk for ...
Cardio Diagnostics’ PrecisionCHD™ test is an AI-powered integrated genetic-epigenetic test to aid in the diagnosis and management of CHD. The six DNA methylation markers evaluated by the PrecisionCHD™ ...
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in most developed countries. Among markers of CVD, arterial stiffness has proven to be an important parameter in the ...
Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy With improved cancer treatments and a rising survivorship population, it is ...
The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results